Outset Medical Achieves Record 43.4% Gross Margin in Q1, Reaffirms Annual Forecast
OM sits 35% above its 52-week low of $3.
Summary
Outset Medical reported Q1 results, achieving a record gross margin of 43.4%, driven by disciplined execution and expanding service margins. This operational improvement comes despite a 6% year-over-year revenue decline to $27.9 million. The company reiterated its full-year 2026 revenue guidance of $125 million to $130 million and non-GAAP gross margin guidance in the low to mid-40% range. This record gross margin builds on the expanded margins noted in the recent 10-K, indicating continued progress in profitability. While revenue growth remains a challenge, the significant margin expansion is a key positive operational development, suggesting improved efficiency. Investors will closely watch future revenue trends and sustained margin expansion as the company works towards profitability.
At the time of this announcement, OM was trading at $4.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.6M. The 52-week trading range was $3.00 to $21.98. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.